Recombinant Human Anti-BAFF x Human Anti-IL17 Bispecific Antibody (Minibody) (MiniB-H199)

Recombinant Anti-BAFF x Anti-IL17 Bispecific Antibody (Minibody) is designed to be expressed as the anti-BAFF scFv fused to N-terminus of Knob-CH3 domain and the anti-IL17 scFv to the Hole-CH3 domain, or vice versa. The CH3 domains are further stabilized by C-terminal disulfide bonds. This BsAb can neutralize both BAFF and IL- 17 simultaneously. It is designed for the research of Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA); Psoriasis (Ps); Ankylosing Spondylitis (AS); Psoriatic Arthritis (PA) primary Sjögren's Syndrome (pSS); Multiple Myeloma (MM) therapy.

Datasheet INQUIRY

Specifications

Targets

BAFF & IL17

Type

Minibody

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lupus Nephritis (LN); Systemic Lupus Erythematosus (SLE); Rheumatoid Arthritis (RA); Psoriasis (Ps); Ankylosing Spondylitis (AS); Psoriatic Arthritis (PA) primary Sjögren's Syndrome (pSS); Multiple Myeloma (MM)

Targets

Target 1

BAFF

Gene ID

10673

UniProt ID

Q9Y275

Alternative Names

TNFSF13B; TNF superfamily member 13b; DTL; B cell activating factor; BAFF; BLYS; CD257; TALL1; THANK; ZTNF4; TALL-1; TNFSF20

Target 2

IL17

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-BAFF x Human Anti-IL17 Bispecific Antibody (Minibody) (MiniB-H199). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-BAFF x Human Anti-IL17 Bispecific Antibody (Minibody) (CAT#: MiniB-H199)

Specifications

Targets

Customer Reviews and Q&As